---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-223659"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2021-07-26T23:59:59+00:00"
generated_at: "2026-06-30T02:33:46.102968+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Apellis closes exchange of $201.1M convertible notes for 5.99M common shares

## Summary
- Exchanged $201.1M principal of 3.500% Convertible Senior Notes due 2026 for 5,992,217 common shares.
- After exchange, approximately $192.7M principal amount of Notes remain outstanding with third parties.
- Transaction closed on July 23, 2021; shares issued are unregistered and restricted.
- Privately negotiated exchange reduces debt and dilutes existing equity by ~3% based on prior share count.

## SEC filing metadata
- accession: 0001193125-21-223659
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2021-07-26T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312521223659/0001193125-21-223659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312521223659/d217083d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-223659
- JSON: https://secwatch.observer/filing/0001193125-21-223659.json
- Plain text: https://secwatch.observer/filing/0001193125-21-223659.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.